Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed
Jazz Pharmaceuticals stock has more than doubled over the past year, yet current market multiples still suggest the shares may be pricing in less optimism than the recent performance and deal activity might imply.
- The share price has returned 112.6% over the last 12 months, which raises the question of how much of Jazz Pharmaceuticals' recent momentum is already reflected in today’s valuation.
- Investors are weighing the potential value from the planned Actio Biosciences acquisition and an expanding epilepsy and oncology portfolio against ongoing risks around pricing pressure, regulatory outcomes and execution on the broader pipeline.
- Jazz Pharmaceuticals scores 4 out of 6 on our valuation checks, which points to a mixed picture rather than a clear bargain or clear overvaluation.
The issue now is whether Jazz Pharmaceuticals' current price still leaves a reasonable margin between what you pay today and what the fundamentals appear to justify.
Is Jazz Pharmaceuticals a Bargain on Earnings?
The P/E ratio is a useful metric for Jazz Pharmaceuticals because earnings are a key focus for investors in profitable specialty pharma companies. Jazz Pharmaceuticals currently trades on a P/E of 17.2x, which is almost identical to the wider pharmaceuticals industry average of 17.2x. Compared with a peer group average of 28.8x, the stock trades at a sizeable discount on this earnings measure.
A fair P/E ratio for Jazz Pharmaceuticals, based on its profile, is estimated at 24.7x. This is meaningfully above the current 17.2x multiple. The difference implies the market is assigning a lower earnings valuation than this framework suggests might be reasonable. Despite the recently announced Actio Biosciences deal and record Q2 2026 revenue, the market is not pricing Jazz Pharmaceuticals at a premium to its sector or peers.
On the P/E multiple, Jazz Pharmaceuticals stock appears undervalued relative to both its tailored fair ratio and its peer group.
See what the numbers say about this price — find out in our valuation breakdown.
The Jazz Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives step in here to spell out what would need to happen with Jazz Pharmaceuticals' growth, margins and earnings for the stock to be worth materially more or less than where it trades today, using those assumptions as the bridge from the valuation puzzle above. Rather than relying on a single multiple or model output, each Narrative lays out the drivers behind its view of fair value so you can compare those assumptions with future results on the Community page.
Community views on Jazz Pharmaceuticals sit far apart, with one camp focused on oncology and new launches and the other on patent and pricing risk.
Bull case: roughly fairly valued
"Recent acquisition of Chimerix and other disciplined corporate development initiatives are diversifying Jazz's portfolio, extending patent life on new assets, and reducing reliance on legacy products…"
Read the full Bull Case to see why Jazz Pharmaceuticals could be undervalued
Bear case: 17% overvalued
"Revenue and margins face threats from upcoming patent expirations, generic competition, and global pricing pressures, especially in the sleep and rare disease franchises…"
Read the full Bear Case to see why Jazz Pharmaceuticals could be overvalued
Do you think there's more to the story for Jazz Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
Jazz Pharmaceuticals screens as undervalued on its current P/E multiples, which points to the market still applying a discount despite the recent re-rating. The value checks are mixed rather than emphatic, so the current setup looks more like a measured opportunity than a clear mispricing. The key question from here is whether Jazz Pharmaceuticals can execute on its epilepsy and oncology pipeline while managing pricing and patent risks so that earnings support, or eventually lift, today’s multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com